REFERENCES
- Bode W., Turk D., Karshikov A. The refined 1.9-A X-ray crystal structure of D-Phe-Pro-Arg chloromethylketone-inhibited human a-thrombin. Protein Sci. 1992; 1: 426–471, [INFOTRIEVE], [CSA]
- Coughlin S. R. Thrombin signaling and protease-activated receptors. Nature 2000; 407: 258–264, [INFOTRIEVE], [CROSSREF], [CSA]
- Papaconstantinou M., Carrell C. J., Pineda A. O., Bobofchak K. E., Mathews F. S., Flordellis C. S., Maragoudakis M. E., Tsopanoglou N. E., Di Cera E. Thrombin functions through its RGD sequence in a non-canonical conformation. J Biol Chem. 2005; 280: 29393–29396, [INFOTRIEVE], [CROSSREF], [CSA]
- Tsopanoglou N. E., Andriopoulou P., Maragoudakis M. E. On the mechanism of thrombin-induced angiogenesis: Involvement of ανβ3 integrin. Am J Physiol—Cell Physiology 2002; 283: C1501–C1510, [CSA]
- Tsopanoglou N. E., Maragoudakis M. E. Role of thrombin in angiogenesis and tumor progression. Sem Thromb Haemost 2004; 30: 63–69, [CROSSREF], [CSA]
- Tsopanoglou N. E., Papaconstantinou M., Flordellis C. S., Maragoudakis M. E. On the mode of action of thrombin-induced angiogenesis: Thrombin peptide, TP508, mediates effects in endothelial cells via α ν β 3 integrin. Thromb Haemost 2004; 92: 846–857, [INFOTRIEVE], [CSA]
- Ahn H.-S., Foster C., Boykow G., Stamford A., Manna M., Graziano M. Inhibition of cellular action of thrombin by N3-cuclopropyl-7-{[4-(1-methylethyl)phenyl]methyl}-7H-pyrrolo[3,2-f]quinazoline-1,3-diamine (SCH79797), a nonpeptide thrombin receptor antagonist. Biochem Pharmacol 2000; 60: 1425–1434, [INFOTRIEVE], [CROSSREF], [CSA]
- Andrande-Gordon P., Maryanoff B. E., Derian C. K., Zhang H.-C., Addo M. F., Darrow A. L., Eckardt A. J., Hoekstra J., McComsey D. F., Oksenberg D., Reynolds E. E., Santulli R., Scarborough R. M., Smith C. E., White B. Design, synthesis and biological characterization of a peptide-mimetic antagonist for a tethered-ligand receptor. Proc Natl Acad Sci USA 1999; 96: 12257–12262, [CROSSREF], [CSA]
- Coughlin S. R. Protease-activated receptors in haemostasis, thrombosis and vascular biology. J Thromb Haemost 2005; 3: 1800–1814, [INFOTRIEVE], [CROSSREF], [CSA]
- Derian C. K., Damiano B. P., Addo M. F., Darrow A. L., D'Andrea M. R., Nedelman M., Zhang H.-C., Maryanoff B. E., Andrande-Gordon P. Blockage of the thrombin receptor protease-activated receptor-1 with a small-molecule antagonist prevents thrombus formation and vascular occlusion in nonhuman primates. J Pharmacol Exp Ther 2003a; 304: 855–861, [INFOTRIEVE], [CROSSREF], [CSA]
- Derian C. K., Maryanoff B. E., Andrande-Gordon P., Zhang H.-C. Design and evaluation of potent peptide-mimetic PAR1 antagonists. Drug Dev Res 2003b; 59: 355–366, [CROSSREF], [CSA]
- Fiorucci S., Antonelli E., Distrutti E., Severino B., Fiorentina R., Baldoni M., Galiando G., Santagada V., Morelli A., Cirino G. PAR1 antagonism protects against experimental liver fibrosis. Role of proteinase receptors in stellate cell activation. Hepatology 2004; 39: 365–375, [INFOTRIEVE], [CROSSREF], [CSA]
- Martin C. B., Mahon G. M., Klinger M. B., Kay R. J., Symons M., Der C. J., Whitehead I. P. The thrombin receptor, PAR-1, causes transformation by activation of Rho-mediated signaling pathways. Oncogene 2001; 20: 1953–1963, [INFOTRIEVE], [CROSSREF], [CSA]
- Ossovskaya V. S., Bunnett N. W. Protease-activated receptors: Contribution to physiology and disease. Physiol Rev. 2004; 84: 579–621, [INFOTRIEVE], [CROSSREF], [CSA]
- Tsopanoglou N. E., Maragoudakis M. E. Role of thrombin in angiogenesis and tumor progression. Sem Thromb Haemost 2004; 30: 63–69, [CROSSREF], [CSA]
- Vergnolle N., Cellar L., Mercarelli A., Rizzo G., Swaminathan S., Beck P., Steinhoff M., Andrande-Gordon P., Bunnett N. W., Hollenberg M. D., Wallace J. L., Cirino G., Fiorucci S. A role for proteinase-activated receptor-1 in inflammatory bowel diseases. J Clin Invest 2004; 114: 1444–1456, [INFOTRIEVE], [CROSSREF], [CSA]
- Vu T.-K. H., Hung D. T., Wheaton V. I., Coughlin S. R. Molecular cloning of a functional thrombin receptor reveals a novel proteolytic mechanism of receptor activation. Cell 1991; 64: 1057–1068, [INFOTRIEVE], [CROSSREF], [CSA]
- Zania P., Kritikou S., Flordellis C. S., Maragoudakis M. E., Tsopanoglou N. E. Blockage of angiogenesis by small molecule antagonists to protease-activated receptor-1: Association with endothelial cell growth suppression and induction of apoptosis. J Pharmacol Exp Ther 2006, in press[CSA]
- Amin D. N., Hida K., Bielenberg D. R. Tumor endothelial cells express epidermal growth factor receptor (EGFR) but not ErbB3 and are responsive to EGF and to EGFR kinase inhibitors. Cancer Res. 2006; 66: 2173–2180, [INFOTRIEVE], [CROSSREF], [CSA]
- Bozec A., Formento P., Ciccolini J., et al. Response of endothelial cells to a dual tyrosine kinase receptor inhibition combined with irradiation. Mol Cancer Ther. 2005; 4: 1962–1971, [INFOTRIEVE], [CROSSREF], [CSA]
- Chakravarti A., Chakladar A., Delaney M. A., Latham D. E., Loeffler J. S. The epidermal growth factor receptor pathway mediates resistance to sequential administration of radiation and chemotherapy in primary glioblastoma cells in a RAS-dependent manner. Cancer Res. 2002; 62: 4307–4315, [INFOTRIEVE], [CSA]
- Ciardiello F., Caputo R., Bianco R., et al. Inhibition of growth factor production and angiogenesis in human cancer cells by ZD1839 (Iressa), a selective epidermal growth factor receptor tyrosine kinase inhibitor. Clin Cancer Res. 2001; 7: 1459–65, [INFOTRIEVE], [CSA]
- Frederick B., Gustafson D., Bianco C., et al. ZD6474, an inhibitor of VEGFR and EGFR tyrosine kinase activity in combination with radiotherapy. Int J Rad Oncol Biol Phys. 2006; 64: 33–37, [CROSSREF], [CSA]
- Hainsworth J. D., Sosman J. A., Spigel D. R., et al. Treatment of metastatic renal carcinoma with a combination of bevacizumab and erlotinib. J Clin Oncol. 2005; 23: 7889–7896, [INFOTRIEVE], [CROSSREF], [CSA]
- Herbst R. S., Johnson D. H., Mininberg E., et al. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol. 2005; 23: 2544–2555, [INFOTRIEVE], [CROSSREF], [CSA]
- Huang S. M., Li J., Harari P. M. Molecular inhibition of angiogenesis and metastatic potential in human squamous cell carcinomas after epidermal growth factor receptor blockade. Mol Cancer Ther. 2002; 1: 507–14, [INFOTRIEVE], [CSA]
- Iivanainen E., Nelimarkka L., Elenius V., et al. Angiopoietin-regulated recruitment of vascular smooth muscle cells by endothelial-derived heparin binding EGF-like growth factor. FASEB J. 2003; 17: 1609–21, [INFOTRIEVE], [CROSSREF], [CSA]
- Perez-Soler R., Piperdi B., Haigentz M., Ling Y. H. Determinants of sensitivity to the EGFR TK inhibitor erlotinib (E) in a panel of NSCLC cell lines. Proc Am Soc Clin Oncol. 2004; 7026, [CSA]
- Qiu L., Di W., Jiang Q., et al. Targeted inhibition of transient activation of the EGFR-mediated cell survival pathway enhances paclitaxel-induced ovarian cancer cell death. Int J Oncol. 2005; 27: 1441–1448, [INFOTRIEVE], [CSA]
- van Cruijsen H., Giaccone G., Hoekman K. Epidermal growth factor receptor and angiogenesis: opportunities for combined anticancer strategies. Int J Cancer 2005; 118: 883–888, [CROSSREF], [CSA]
- Viloria-Petit A. M., Kerbel R. S. Acquired resistance to EGF inhibitors : mechanisms and prevention strategies. Int J Radiation Oncology Biol Phys. 2004; 58: 914–26, [CROSSREF], [CSA]
- Baksi K., Tavarez-Pagan Martinez J. A., Banerjee D. K. Mannosylphosphodolichol synthase and angiogenesis (2006) Current Trends in Drud Research (invited). 2006, [CSA]
- Martinez J. A., Tavarez J. J., Oliveira C. M., Banerjee D. K. Potentiation of angiogenic switch in capillary endothelial cells by cAMP: A cross-talk between up-regulated LLO biosynthesis and the HSP-70 expression. Glycoconjugate J 2005, (In press)[CSA]
- Tavarez-Pagan J. J., Oliverira C. M., Banerjee D. K. Insulin up-regulates a Glc3Man9GlcNAc2-PP-Dol pool in capillary endothelial cells not essential for angiogenesis. Glycoconjugate J. 2004; 20: 179–188, [CROSSREF], [CSA]
- Hall, Hubbell. Microvas. Res. 2004; 68: 169–178, [CROSSREF], [CSA]
- Hall, et al. Microvasc. Res. 2001; 62: 315–326, [INFOTRIEVE], [CROSSREF], [CSA]
- Hall, et al. Angiogenesis 2004; 7: 213–223, [INFOTRIEVE], [CROSSREF], [CSA]
- Trentin, et al. J. Contr. Rel. 2005; 102: 263–275, [CROSSREF], [CSA]
- Trentin, et al. PNAS 2006, in press[CSA]
- Urech, et al. Biomaterials 2005; 26: 1369–1379, [INFOTRIEVE], [CROSSREF], [CSA]
- Shin M., Matsuda K., Ishii O., Terai H., Kaazempur-Mofrad M., Borenstein J., Detmar M., Vacanti J. P. Endothelialized networks with a vascular geometry in microfabricated poly(dimethyl siloxane). Biomed Microdevices 2004; 6: 269–278, [INFOTRIEVE], [CROSSREF], [CSA]
- Wu X., Rabkin-Aikawa E., Guleserian K. J., Perry T. E., Masuda Y., Sutherland F. W., Schoen F. J., Mayer J. E., Jr., Bischoff J. Tissue-engineered microvessels on three-dimensional biodegradable scaffolds using human endothelial progenitor cells. Am J Physiol Heart Circ Physiol 2004; 287: H480–H487, [INFOTRIEVE], [CROSSREF], [CSA]
- Dowlati A., Robertson K., Radivovyevitch T., et al. Novel phase I dose de-escalation design trial to determine the biological modulatory dose of the antiangiogenic agent SU5416. Clin Cancer Res. 2005; 11: 7938–44, [INFOTRIEVE], [CROSSREF], [CSA]
- Hurwitz H., Fehrenbacher L., Novotny W., et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med. 2004; 350: 2335–42, [INFOTRIEVE], [CROSSREF], [CSA]
- Kuenen B. C., Giaccone G., Ruijter R., et al. Dose-finding study of the multitargeted tyrosine kinase inhibitor SU6668 in patients with advanced malignancies. Clin Cancer Res. 2005; 11: 6240–6, [INFOTRIEVE], [CROSSREF], [CSA]
- Kuenen B. C., Levi M., Meijers J. C., et al. Potential role of platelets in endothelial damage observed during treatment with cisplatin, gemcitabine, and the angiogenesis inhibitor SU5416. J Clin Oncol 2003a; 21: 2192–8, [INFOTRIEVE], [CROSSREF], [CSA]
- Kuenen B. C., Tabernero J., Baselga J., et al. Efficacy and toxicity of the angiogenesis inhibitor SU5416 as a single agent in patients with advanced renal cell carcinoma, melanoma, and soft tissue sarcoma. Clin Cancer Res. 2003b; 9: 1648–55, [INFOTRIEVE], [CSA]
- Morgan B., Thomas A. L., Drevs J., et al. Dynamic contrast-enhanced magnetic resonance imaging as a biomarker for the pharmacological response of PTK787/ZK 222584, an inhibitor of the vascular endothelial growth factor receptor tyrosine kinases, in patients with advanced colorectal cancer and liver metastases: results from two phase I studies. J Clin Oncol. 2003; 21: 3955–64, [INFOTRIEVE], [CROSSREF], [CSA]
- Motzer R. J., Michaelson M. D., Redman B. G., et al. Activity of SU11248, a multitargeted inhibitor of vascular endothelial growth factor receptor and platelet-derived growth factor receptor, in patients with metastatic renal cell carcinoma. J Clin Oncol. 2006; 24: 16–24, [INFOTRIEVE], [CROSSREF], [CSA]
- Tyagi P. Vatalanib (PTK787/ZK 222584) in combination with FOLFOX4 versus FOLFOX4 alone as first-line treatment for colorectal cancer: preliminary results from the CONFIRM-1 trial. Clin Colorectal Cancer 2005; 5: 24–6, [INFOTRIEVE], [CSA]
- Willett C. G., Boucher Y., di Tomaso E., et al. Direct evidence that the VEGF-specific antibody bevacizumab has antivascular effects in human rectal cancer. Nat Med. 2004; 10: 145–7, [INFOTRIEVE], [CROSSREF], [CSA]
- Yang J. C., Haworth L., Sherry R. M., et al. A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer. N Engl J Med. 2003; 349: 427–34, [INFOTRIEVE], [CSA]
- Polykratis A., et al. Int. J. Biochem. Cell Biol. 2004; 36: 1954–1966, [INFOTRIEVE], [CSA]
- Rauvala H. EMBO J. 1989; 8: 2933–2941, [INFOTRIEVE], [CSA]
- Wellstein A., et al. J. Biol. Chem. 1992; 267: 2582–2587, [INFOTRIEVE], [CSA]